argenex (NASDAQ:ARGX) Price Target Raised to $1,000.00

argenex (NASDAQ:ARGX) had its price objective upped by Wedbush from $880.00 to $1,000.00 in a report issued on Friday morning, MarketBeat.com reports. They currently have an outperform rating on the stock. Wedbush also issued estimates for argenex’s Q4 2025 earnings at $6.48 EPS, Q1 2026 earnings at $7.36 EPS, Q2 2026 earnings at $8.16 EPS, Q3 2026 earnings at $8.95 EPS, Q4 2026 earnings at $9.60 EPS, FY2026 earnings at $34.10 EPS, FY2027 earnings at $46.09 EPS and FY2028 earnings at $61.81 EPS.

A number of other analysts have also commented on ARGX. Zacks Research lowered argenex from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, October 21st. HC Wainwright raised their price target on shares of argenex from $774.00 to $915.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Royal Bank Of Canada boosted their price objective on shares of argenex from $850.00 to $860.00 and gave the company an “outperform” rating in a research report on Friday, October 31st. Weiss Ratings reissued a “hold (c)” rating on shares of argenex in a research note on Wednesday, October 8th. Finally, Deutsche Bank Aktiengesellschaft cut shares of argenex from a “buy” rating to a “hold” rating in a research note on Thursday, September 11th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $885.94.

argenex Trading Up 1.8%

Shares of NASDAQ ARGX opened at $907.98 on Friday. The stock has a market cap of $55.90 billion, a price-to-earnings ratio of 38.99, a PEG ratio of 0.93 and a beta of 0.45. The company’s 50-day moving average price is $799.34 and its 200 day moving average price is $672.81. argenex has a 52 week low of $510.05 and a 52 week high of $914.87.

argenex (NASDAQ:ARGX) last released its quarterly earnings results on Thursday, October 30th. The company reported $4.40 EPS for the quarter, beating the consensus estimate of $4.37 by $0.03. argenex had a net margin of 41.58% and a return on equity of 29.78%. The business had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.07 billion. As a group, research analysts expect that argenex will post 3.13 earnings per share for the current year.

Institutional Investors Weigh In On argenex

Institutional investors have recently added to or reduced their stakes in the company. Ameriflex Group Inc. purchased a new position in shares of argenex in the 3rd quarter worth about $32,000. WPG Advisers LLC purchased a new position in argenex in the first quarter valued at approximately $37,000. Brooklyn Investment Group raised its holdings in argenex by 102.7% in the first quarter. Brooklyn Investment Group now owns 75 shares of the company’s stock valued at $44,000 after buying an additional 38 shares during the period. Bessemer Group Inc. grew its stake in argenex by 276.5% during the third quarter. Bessemer Group Inc. now owns 64 shares of the company’s stock worth $47,000 after buying an additional 47 shares during the period. Finally, MAI Capital Management grew its stake in argenex by 866.7% during the second quarter. MAI Capital Management now owns 87 shares of the company’s stock worth $48,000 after buying an additional 78 shares during the period. Hedge funds and other institutional investors own 60.32% of the company’s stock.

About argenex

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.